Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2- advanced breast cancer: from prognostic biomarker to clinical decision-making - a comprehensive review.
Blood-based genetic monitoring of breast cancer mutations now guides real-time therapy switches, reducing progression risk by 56% compared to standard care.
Systematic review of 9 studies finds ctDNA ESR1 mutation monitoring in HR+/HER2- breast cancer has evolved from a prognostic biomarker into an actionable clinical decision node, with SERENA-6 demonstrating pre-emptive therapeutic switching reduces progression risk by 56%. Dynamic ctDNA ESR1 monitoring represents a transformative approach to real-time precision therapy adaptation in metastatic breast cancer.
What the study was
- Study design
- PRISMA systematic review; 9 high-quality studies of ctDNA ESR1 mutations in CDK4/6i + ET-treated HR+/HER2- breast cancer.
- Population
- HR+/HER2- metastatic breast cancer patients receiving CDK4/6 inhibitors plus endocrine therapy.
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Frontiers in Oncology
Why it surfaced
Timely synthesis of ctDNA ESR1 monitoring evidence with SERENA-6 clinical validation; relevant to most common breast cancer subtype.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.